BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories

Ettore Capoluongo, Nicla La Verde, Massimo Barberis, Maria Angela Bella, Fiamma Buttitta, Paola Carrera, Nicoletta Colombo, Laura Cortesi, Maurizio Genuardi, Massimo Gion, Valentina Guarneri, Domenica Lorusso, Antonio Marchetti, Paolo Marchetti, Nicola Normanno, Barbara Pasini, Matilde Pensabene, Sandro Pignata, Paolo Radice, Enrico RicevutoAnna Sapino, Pierosandro Tagliaferri, Pierfrancesco Tassone, Chiara Trevisiol, Mauro Truini, Liliana Varesco, Antonio Russo, Stefania Gori

Research output: Contribution to journalArticle

Abstract

In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for BRCA1/2. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing BRCA1/2 germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.

Original languageEnglish
Article number46
JournalDiagnostics
Volume9
Issue number4
DOIs
Publication statusPublished - Dec 1 2019

Fingerprint

Oncology
Molecular Pathology
Ovarian Neoplasms
Assays
Medical Oncology
Surveys and Questionnaires
Molecular biology
Italy
Counseling
Molecular Biology
Throughput

Keywords

  • BRCA1/2 assays
  • NGS
  • PARP-1i
  • Somatic BRCA

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

BRCA1/2 molecular assay for ovarian cancer patients : A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories. / Capoluongo, Ettore; La Verde, Nicla; Barberis, Massimo; Bella, Maria Angela; Buttitta, Fiamma; Carrera, Paola; Colombo, Nicoletta; Cortesi, Laura; Genuardi, Maurizio; Gion, Massimo; Guarneri, Valentina; Lorusso, Domenica; Marchetti, Antonio; Marchetti, Paolo; Normanno, Nicola; Pasini, Barbara; Pensabene, Matilde; Pignata, Sandro; Radice, Paolo; Ricevuto, Enrico; Sapino, Anna; Tagliaferri, Pierosandro; Tassone, Pierfrancesco; Trevisiol, Chiara; Truini, Mauro; Varesco, Liliana; Russo, Antonio; Gori, Stefania.

In: Diagnostics, Vol. 9, No. 4, 46, 01.12.2019.

Research output: Contribution to journalArticle

Capoluongo, Ettore ; La Verde, Nicla ; Barberis, Massimo ; Bella, Maria Angela ; Buttitta, Fiamma ; Carrera, Paola ; Colombo, Nicoletta ; Cortesi, Laura ; Genuardi, Maurizio ; Gion, Massimo ; Guarneri, Valentina ; Lorusso, Domenica ; Marchetti, Antonio ; Marchetti, Paolo ; Normanno, Nicola ; Pasini, Barbara ; Pensabene, Matilde ; Pignata, Sandro ; Radice, Paolo ; Ricevuto, Enrico ; Sapino, Anna ; Tagliaferri, Pierosandro ; Tassone, Pierfrancesco ; Trevisiol, Chiara ; Truini, Mauro ; Varesco, Liliana ; Russo, Antonio ; Gori, Stefania. / BRCA1/2 molecular assay for ovarian cancer patients : A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories. In: Diagnostics. 2019 ; Vol. 9, No. 4.
@article{395e3c960eeb485b8a94b1add42f8cfe,
title = "BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories",
abstract = "In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for BRCA1/2. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25{\%}) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70{\%}) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing BRCA1/2 germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.",
keywords = "BRCA1/2 assays, NGS, PARP-1i, Somatic BRCA",
author = "Ettore Capoluongo and {La Verde}, Nicla and Massimo Barberis and Bella, {Maria Angela} and Fiamma Buttitta and Paola Carrera and Nicoletta Colombo and Laura Cortesi and Maurizio Genuardi and Massimo Gion and Valentina Guarneri and Domenica Lorusso and Antonio Marchetti and Paolo Marchetti and Nicola Normanno and Barbara Pasini and Matilde Pensabene and Sandro Pignata and Paolo Radice and Enrico Ricevuto and Anna Sapino and Pierosandro Tagliaferri and Pierfrancesco Tassone and Chiara Trevisiol and Mauro Truini and Liliana Varesco and Antonio Russo and Stefania Gori",
year = "2019",
month = "12",
day = "1",
doi = "10.3390/diagnostics9040146",
language = "English",
volume = "9",
journal = "Diagnostics",
issn = "2075-4418",
publisher = "MDPI AG",
number = "4",

}

TY - JOUR

T1 - BRCA1/2 molecular assay for ovarian cancer patients

T2 - A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories

AU - Capoluongo, Ettore

AU - La Verde, Nicla

AU - Barberis, Massimo

AU - Bella, Maria Angela

AU - Buttitta, Fiamma

AU - Carrera, Paola

AU - Colombo, Nicoletta

AU - Cortesi, Laura

AU - Genuardi, Maurizio

AU - Gion, Massimo

AU - Guarneri, Valentina

AU - Lorusso, Domenica

AU - Marchetti, Antonio

AU - Marchetti, Paolo

AU - Normanno, Nicola

AU - Pasini, Barbara

AU - Pensabene, Matilde

AU - Pignata, Sandro

AU - Radice, Paolo

AU - Ricevuto, Enrico

AU - Sapino, Anna

AU - Tagliaferri, Pierosandro

AU - Tassone, Pierfrancesco

AU - Trevisiol, Chiara

AU - Truini, Mauro

AU - Varesco, Liliana

AU - Russo, Antonio

AU - Gori, Stefania

PY - 2019/12/1

Y1 - 2019/12/1

N2 - In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for BRCA1/2. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing BRCA1/2 germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.

AB - In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for BRCA1/2. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing BRCA1/2 germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.

KW - BRCA1/2 assays

KW - NGS

KW - PARP-1i

KW - Somatic BRCA

UR - http://www.scopus.com/inward/record.url?scp=85076809612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076809612&partnerID=8YFLogxK

U2 - 10.3390/diagnostics9040146

DO - 10.3390/diagnostics9040146

M3 - Article

AN - SCOPUS:85076809612

VL - 9

JO - Diagnostics

JF - Diagnostics

SN - 2075-4418

IS - 4

M1 - 46

ER -